Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.

NEW YORK, Aug 13 (Reuters) - Drugmakers Pfizer Inc, BioNTech and Moderna Inc are expected to reap billions of dollars from COVID-19 booster shots in a market that could rival the $6 billion in annual ...

After losing nearly half its value from its 2021 highs, Pfizer stock (NYSE: PFE) now trades at about $25, presenting a potentially attractive value setup. As the company continues to adapt to a ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

Pfizer's >7% dividend yield is attractive, but faces significant risk due to political, regulatory, and business headwinds impacting revenue and profitability. Major threats include U.S. healthcare ...

Pfizer stock is a deep-value kind of blue chip with a yield of more than 7%. The dividend looks safe — for now. The real question is whether there’s enough growth and innovation in the pipeline as the ...

Its March 20 $29 put had the highest unusual options activity on the day with a Vol/OI (volume-to-open-interest) ratio of 210.16, 35% higher than the Alphabet (GOOG) option in second place. Pfizer is ...

Pfizer is deeply undervalued, trading at a multi-year low with a 6.65% dividend yield, making it a compelling long-term opportunity. Recent double-digit earnings growth, strong margins, and cost ...

Both Ford and Pfizer have very attractive dividend yields.